Neuropathix

At last week's BioNJ BioPartnering Conference, CEO Dean Petkanas of Neuropathix featured in ROI-NJ, where he highlighted New Jersey's prominent role in the pharmaceutical biotech sector. It's clear that NJ remains a top choice for life science startups and the state continues to draw interest due to its strong infrastructure and support.

At BioPartnering event, it’s easy to find cheerleaders for (and critics of) state | ROI-NJ Dean Petkanas is the CEO of prerevenue Neuropathix, a Doylestown, Pennsylvania-based company, one of 90 that came to BioNJ’s BioPartnering Conference on Tuesday looking to make connections. And, if he’s looking for another job, he appears to be a prime candidate to be a spokesperson/cheerleader ...

Neuropathix CEO Dean Petkanas pens Op-Ed on Why Opioids controlled the Pain Management Market and What's Next.

Why Opioids Controlled the Pain Management Market for So Long and for All the Wrong Reasons: Here’s What’s Next It’s no secret that the pain management market is booming.

Neuropathix CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding

Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding DOYLESTOWN, PA / ACCESSWIRE / April 6, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today that its CEO Dean Petkanas has issued a letter to its shareholders, providing commentary on the Company's recen...

CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
$NPTX